B Biogen
American pharmaceutical company
Updates & Highlights
WilmerHale · about 21 hours ago
WilmerHale Advises Biogen in Acquisition of RayThera
Investing.com · 1 day ago
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook
Stocktwits · 1 day ago
BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal
Recent Openings
View all 1 jobs arrow_forwardMachine Learning Engineer, Operations and Health Systems Research
location_on Cambridge, MA, US
All Jobs
Machine Learning Engineer, Operations and Health Systems Research
location_on Cambridge, MA, US
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Generous PTO
Paid time off
Parental Leave
Family-friendly policies
Competitive Salary
Market-rate compensation
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Biogen?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentWilmerHale Advises Biogen in Acquisition of RayThera
WilmerHale Advises Biogen in Acquisition of RayThera
WilmerHale · about 21 hours ago
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook
Investing.com · 1 day ago
BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal
BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal
Stocktwits · 1 day ago
Biogen (BIIB) Stock Could Be 10.3% Undervalued on Its Pipeline Narrative
Biogen (BIIB) Stock Could Be 10.3% Undervalued on Its Pipeline Narrative
Yahoo Finance · 4 days ago
Biogen acquires immunology start-up RayThera for $1bn
Biogen acquires immunology start-up RayThera for $1bn
European Pharmaceutical Review · 4 days ago
Biogen to acquire RayThera for up to $1bn
Biogen to acquire RayThera for up to $1bn
Pharmaceutical Technology · 4 days ago
Biogen acquires RayThera for up to $1 billion
Biogen acquires RayThera for up to $1 billion
BioXconomy · 4 days ago
Biogen snaps up RayThera in $1B immunology deal
Biogen snaps up RayThera in $1B immunology deal
FirstWord Pharma · 5 days ago
Friday Five – FDA flexibility, Biogen's latest bolt-on, Intellia's CRISPR case may be needle in a HAE-stack…and more
Friday Five – FDA flexibility, Biogen's latest bolt-on, Intellia's CRISPR case may be needle in a HAE-stack…and more
FirstWord Pharma · 5 days ago
Biogen To Acquire RayThera For Up To $1 Billion
Biogen To Acquire RayThera For Up To $1 Billion
Pulse 2.0 · 5 days ago
Recon: Biogen to acquire RayThera for $1B; FDA approves first generic version Roche flu drug
Recon: Biogen to acquire RayThera for $1B; FDA approves first generic version Roche flu drug
RAPS.org · 5 days ago
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
BioPharma Dive · 5 days ago
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
Benzinga · 5 days ago
Biogen Enters $1 Billion Agreement to Acquire RayThera Inc.
Biogen Enters $1 Billion Agreement to Acquire RayThera Inc.
Pharmaceutical Executive · 5 days ago
Biogen snags San Diego biotech for $1B as immunology expansion continues
Biogen snags San Diego biotech for $1B as immunology expansion continues
The Business Journals · 5 days ago
Biogen acquires RayThera in deal worth up to $1 billion
Biogen acquires RayThera in deal worth up to $1 billion
qz.com · 5 days ago
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
Zacks Investment Research · 5 days ago
New biotech boom: Biogen to buy RayThera for $1bn
New biotech boom: Biogen to buy RayThera for $1bn
EMJ · 5 days ago
Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says
Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says
marketscreener.com · 5 days ago
Biogen Agrees to Acquire RayThera for Up to $1B
Biogen Agrees to Acquire RayThera for Up to $1B
Contract Pharma · 5 days ago